GlaxoSmithKline confirms that the EMEA’s Committee for Medicinal Products for Human Use(CHMP) has completed its benefit risk review of the Thiazolidinediones (TZD) class and have concluded that the benefits of rosiglitazone continue to outweigh the risks.
“The EMEA has completed its review and recognises the positive benefit risk of rosiglitazone in Europe and its importance in the treatment of patients with type 2 diabetes,” said Dr Alastair Benbow, Vice President and European Medical Director, GSK. “GSK is confident in the safety profile of rosiglitazone when used appropriately by physicians.”
GSK will continue to work with the agency on appropriate wording for the SPC in order to help physicians provide the best treatment guidance to patients.
GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
— Article compiled by Dr. Anil Singhal, MD(Hom.) from medical news release.